Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis

• Patients over 19 under 75 years of age
• Patients with non-alcoholic fatty liver disease except for cirrhosis
• Patients who have abnormal ALT, AST
• Patients who are satisfied with laboratory test
• Patients who agree to contraception
• Patients who can keet the diet

Exclusion Criteria:

• Over 2 ratio of AST to ALT
• Type 1 diabetes mellitus (insulin-dependent diabetes mellitus) or Type 2 diabetes mellitus(not controlled)
• Disorder in liver function with an exception of non-alcoholic fatty liver
• Patients with malignant tumors
• Patients who have been taken drugs induced fatty liver within 8 weeks of participation in this study
• Patients who has been taken any medications that could affect the treatment for NAFLD within 4 weeks
• Patients who have been taken Vitamin E (≥ 800 IU/day), thiazolidinediones, orlistat within 12 weeks
• Patients who had a Bariatric surgery less than 6 month prior to the participation in the study
• Patients who are judged by investigator that participation of the study is difficult due to disease as follow;
• Any history of immune disorder
• Patients who have received treatment that may affect liver function within 1 month prior to the participation in the study
• Patient who has been administered other investigational product within 1 month prior to the participation in the study
• Patient who is not allowed to get MRS test: pacemaker, shunt and etc
• Pregnant or nursing women
• anti-HIV antibody (+)
• Patient who considered ineligible for participation in the study as Investigator's judgment